Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk‐Stratification, and Treatment

Study limitation reported by the research below: “Treatment sequencing recommendations for relapsed/refractory HCL are not yet evidence-based per the authors — the optimal order of targeted agents remains to be determined.”